Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metab… Read more
Innovent Biologics Inc (IVBXF) - Total Liabilities
Latest total liabilities as of June 2025: $9.17 Billion USD
Based on the latest financial reports, Innovent Biologics Inc (IVBXF) has total liabilities worth $9.17 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Innovent Biologics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Innovent Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Innovent Biologics Inc Competitors by Total Liabilities
The table below lists competitors of Innovent Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samsung Fire And Marine Ins Pref
KO:000815
|
Korea | ₩71.79 Trillion |
|
EDP - Energias de Portugal S.A
OTCGREY:ELCPF
|
USA | $37.51 Billion |
|
Fresenius Medical Care AG & Co. KGaA
PINK:FMCQF
|
USA | $16.98 Billion |
|
GEA GROUP
XETRA:G1A
|
Germany | €3.63 Billion |
|
Aspeed Technology
TWO:5274
|
Taiwan | NT$2.99 Billion |
|
Avidity Biosciences, Inc
NASDAQ:RNAM
|
USA | $269.45 Million |
|
Siemens Healthineers AG
PINK:SEMHF
|
USA | $25.78 Billion |
|
Equitable Holdings Inc
F:AXJ
|
Germany | €312.46 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Innovent Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovent Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovent Biologics Inc (2016–2024)
The table below shows the annual total liabilities of Innovent Biologics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.48 Billion | +4.75% |
| 2023-12-31 | $8.10 Billion | +18.09% |
| 2022-12-31 | $6.86 Billion | +15.99% |
| 2021-12-31 | $5.91 Billion | +93.55% |
| 2020-12-31 | $3.06 Billion | +23.47% |
| 2019-12-31 | $2.47 Billion | +29.00% |
| 2018-12-31 | $1.92 Billion | -52.98% |
| 2017-12-31 | $4.08 Billion | +8.09% |
| 2016-12-31 | $3.77 Billion | -- |